Follow us on Twitter
This page is updated frequently with new Immune Disease-related patent applications. Subscribe to the Immune Disease RSS feed to automatically get the update: related Immune RSS feeds. RSS updates for this page: Immune Disease RSS
|| List of recent Immune Disease-related patents
|Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor|
Benzoimidazol-2-yl pyrimidines, purification methods for the same, and pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritus.. .
|Method of making monomethyl fumarate|
Methods of making monomethyl fumarate, which can then also be used in methods of making prodrugs of monomethyl fumarate, are disclosed. Monomethyl fumarate and prodrugs of monomethyl fumarate are useful for treating neurodegenerative, inflammatory, and autoimmune diseases including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis..
|Triazolopyridine derivatives as a tyrosine kinase inhibitor|
Provided is a novel triazolopyridine derivative having irreversible tyrosine kinase inhibiting activities, and a pharmaceutical composition comprising the same which can be useful for prevention or treatment of inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers or tumors.. .
|Antispasmodic 1,2-diols and 1,2,3-triols|
The present invention is directed to pharmaceutical compositions comprising antispasmodic c4-c8aliphatic-1,2-diols and c4-c8aliphatic-1,2,3-triols and their use to relieve the spasms associated with pain. These agents may be administered topically or orally and may be combined with anti-inflammatory agents such as a non-steroidal anti-inflammatory drug or a corticosteroid.
|Method for increasing specificity of diagnostic tests for autoimmune diseases|
Provided is a method for increasing the specificity of an antibody-based test to help in the diagnosis of autoimmune diseases by contacting a subject's sample with a blocking antigen prior interfering antibody present in the sample. More specifically, a method for increasing specificity of an antibody-based autoimmune disease assay comprising the steps of providing a sample from a subject, contacting the sample with a dfs70 derived antigen, reacting the sample with an autoimmune disease target and detecting antibodies to the autoimmune disease target is disclosed..
|Egfr and par2 regulation of intestinal permeability|
The present invention provides methods for diagnosing an immune-mediated disease, e.g., an autoimmune disease, an allergy or an inflammatory disease. Diagnosis is made by detecting a heterozygous or homozygous genotype of haptoglobin 2 or by detecting and quantifying pre-haptoglobin 2 mrna or protein.
|Core-shell particle formulation for delivering multiple therapeutic agents|
A core-shell particle formulation for delivering multiple therapeutic agents is disclosed. More particularly, core-shell particle formulation configured to independently release therapeutic agents from the core and the shell.
|Nanocell drug delivery system|
Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent.
|Oxidized cardiolipin as a novel pro-inflammatory factor|
Low levels of antibodies reactive with oxidised cardiolipin (oxcl) in mammals are related to an increased risk of developing cardiovascular diseases, auto-immune diseases or inflammatory conditions. High levels can have a protective function and in general there is a negative association between manifestations of these conditions and antibodies against oxcl.
|Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof|
The present invention relates to processes and intermediates useful in the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of formula (ia) and salts thereof, an s1p1 receptor modulator that is useful in the treatment of s1p1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).. .
|Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine h4 receptor|
Diamino-pyridine, pyrimidine and pyridazine compounds which may be used as h4 receptor modulators, and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.. .
|Novel urea and thiourea derivatives|
The present application discloses compounds of formula (i) wherein x is ═o, ═s, ═nh, ═noh and ═no-me; a is —c(═o)—, —s(═o)2—, —c(═s)— and p(═o)(r5)—; b is, —o—, —(ch2)3-6—, and o—(ch2)2-5—; d is, —o—, —cr7r8— and —nr9; m is 0-12, n is 0-12, m+n is 1-20; p is 0-4; r1 is opt.sub. Heteroaryl; and pharmaceutically acceptable salts thereof, and prodrugs thereof.
|Applications of an immune system-released activating agent (israa)|
The present invention relates to applications of an immune system-released activating agent (israa) polypeptide, which is induced by a nervous stimulus and which has been found to mediate the transmission of signals between the immune system and the nervous system following an immune challenge. Here, the israa polypeptide is for use in a method of treatment of patients with immunodeficiency, immunosuppression or autoimmune disease; cancer; neurologic diseases and disorders; or muscular diseases and disorders..
|Polyoma virus jc peptides and proteins in vaccination and diagnostic applications|
The present invention relates to the field of vaccination or immunization, in particular therapeutic vaccination, and diagnosis. Pharmaceutical compositions and kits capable of eliciting a protective immune response against polyoma virus jc (jcv) are disclosed, which may be used e.g., for therapy or for prevention of progressive multifocal leukoencephalopathy (pml) and/or progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome (pml-iris).
|Adoptive cell therapy with specific regulatory lymphocytes|
The present invention comprises a method of treatment of an autoimmune disease involving a specific tolerance induction (“sti”) event, wherein the method includes: collecting a first sample from the patient prior to the sti event; detecting an sti event or performing a procedure that correlates in time to an sti event; collecting a second sample from the patient after the sti event; preparing lymphocytes from the first and second samples; preparing and sequencing dna or cdna from the prepared lymphocytes; identifying sequences of prevalent t or b cell receptors (“prevalent receptor sequences”) among the lymphocytes of the second sample; selecting a regulatory lymphocyte that carries at least one prevalent receptor sequence, which selected regulatory lymphocyte (i) expresses at least one prevalent receptor sequence or (ii) is generated from an autologous or allogeneic naïve lymphocyte, which naïve lymphocyte is engineered and induced to become a regulatory lymphocyte that expresses at least one prevalent receptor sequence; culturing the selected regulatory lymphocyte, thereby generating daughter cells of said regulatory lymphocyte; and administering the daughter cells to the patient.. .
|Compounds and therapeutic uses thereof|
The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, t-cell mediated autoimmune disease, ischemia, and complications associated with these diseases and disorders.. .
|Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rory, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases|
The invention provides modulators for the orphan nuclear receptor rorγ and methods for treating rorγ mediated diseases by administrating these novel rorγ modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo carboxamide compounds of formula (1) and the enantiomers, diastereomers, n-oxides, tautomers, solvates and pharmaceutically acceptable salts thereof..
|Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent|
Disclosed is a therapeutic agent for treating a cellular immune disease, comprising as an active ingredient a substance that inhibits binding between sema3a and a neuropilin-1/plexin-a1 heteroreceptor. The substance includes, for example, a sema3a neutralizing antibody, a neuropilin-1 neutralizing antibody, or a soluble neuropilin-1 or derivative thereof.
|Novel phytosphingosine derivatives, and composition comprising same for preventing and treating inflammatory skin diseases, autoimmune diseases, and hyperkeratosis diseases|
A phytosphingosine derivative of chemical formula ia or ib, and a composition comprising the phytosphingosine derivative for preventing and treating inflammatory skin diseases, autoimmune diseases, and hyperkeratotic diseases. The phytosphingosine derivatives of the present disclosure are involved with transcription factors related to inflammation, autoimmune diseases and hyperkeratotic diseases, the expression and the generation of inflammatory mediators, signal transduction mechanisms, and the expression and the activity of relevant enzymes and the like..
|Methods of monitoring conditions by sequence analysis|
There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer. Provided herein are methods for using dna sequencing to identify personalized biomarkers in patients with autoimmune disease and other conditions.
|Mutant hsp70i to prevent autoimmune disease|
A vaccine and method of treatment suitable for treating autoimmune diseases, such as vitiligo, by using variant peptides representing a sequence of amino acids found in heat shock protein 70. The vaccine includes a peptide derived from inducible heat shock protein 70 and a plasmid containing a full inducible heat shock protein 70 dna sequence encoding the peptide..
|Use of pdl1 expressing cells to convert t cells into regulatory t cells|
The present invention provides methods and compositions for converting a t cell into a cell that exhibits at least one regulatory t cell phenotype. The converted t cell is generated by contacting a t cell with a cell that is modified to comprise an agent capable of activating pd1 signaling in a t cell.
|Human-derived bacteria that induce proliferation or accumulation of regulatory t cells|
Species of human-derived bacteria belonging to the clostridia class have been shown to induce accumulation of regulatory t cells (treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases..
|Anti-human cd52 immunoglobulins|
The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human cd52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain.
Popular terms: [SEARCH]
Immune Disease topics: Immune Disease, Autoimmune, Autoimmune Disease, Immune Diseases, Autoimmune Diseases, Immune Disorder, Transplant, Autoimmune Disorders, Type 1 Diabetes, Autoimmune Disorder, Proliferative Disorder, Signs And Symptoms, Proliferative, Antagonist, Recurrence
Follow us on Twitter
This listing is a sample listing of patent applications related to Immune Disease for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immune Disease with additional patents listed. Browse our RSS directory or Search for other possible listings.